Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

H2S- and NO-releasing gasotransmitter platform: A crosstalk signaling pathway in the treatment of acute kidney injury

Full text
Pieretti, Joana Claudio [1] ; Cruz Junho, Carolina Victoria [1] ; Carneiro-Ramos, Marcela Sorelli [1] ; Seabra, Amedea Barozzi [1]
Total Authors: 4
[1] Fed Univ ABC UFABC, Ctr Nat & Human Sci CCNH, Av Estados 5001, BR-09210580 Santo Andre, SP - Brazil
Total Affiliations: 1
Document type: Review article
Web of Science Citations: 0

Acute kidney injury (AKI) is a syndrome affecting most patients hospitalized due to kidney disease; it accounts for 15 % of patients hospitalized in intensive care units worldwide. AKI is mainly caused by ischemia and reperfusion (IR) injury, which temporarily obstructs the blood flow, increases inflammation processes and induces oxidative stress. AKI treatments available nowadays present notable disadvantages, mostly for patients with other comorbidities. Thus, it is important to investigate different approaches to help minimizing side effects such as the ones observed in patients subjected to the aforementioned treatments. Therefore, the aim of the current review is to highlight the potential of two endogenous gasotransmitters - hydrogen sulfide (H2S) and nitric oxide (NO) - and their crosstalk in AKI treatment. Both H2S and NO are endogenous signalling molecules involved in several physiological and pathophysiological processes, such as the ones taking place in the renal system. Overall, these molecules act by decreasing inflammation, controlling reactive oxygen species (ROS) concentrations, activating/inactivating pro-inflammatory cytokines, as well as promoting vasodilation and decreasing apoptosis, hypertrophy and autophagy. Since these gasotransmitters are found in gaseous state at environmental conditions, they can be directly applied by inhalation, or in combination with H2S and NO donors, which are compounds capable of releasing these molecules at biological conditions, thus enabling higher stability and slow release of NO and H2S. Moreover, the combination between these donor compounds and nanomaterials has the potential to enable targeted treatments, reduce side effects and increase the potential of H2S and NO. Finally, it is essential highlighting challenges to, and perspectives in, pharmacological applications of H2S and NO to treat AKI, mainly in combination with nanoparticulated delivery platforms. (AU)

FAPESP's process: 18/02832-7 - Hybrid magnetic and antibacterial nanoparticles: synthesis, characterization and applications
Grantee:Joana Claudio Pieretti
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 18/03089-6 - Role of the Klotho/FGF23 axis in the development of Type 3 Cardiorenal Syndrome induced by ischemic renal injury
Grantee:Carolina Victória da Cruz Junho
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
FAPESP's process: 18/08194-2 - Essential oil amended with metal nanoparticles functionalized with nitric oxide as a strategy to control plant pathogens in the agriculture
Grantee:Amedea Barozzi Seabra
Support Opportunities: Regular Research Grants
FAPESP's process: 15/19107-5 - TLR4 and complement system : possible key mechanism in renal ischemia/reperfusion induced cardiac hypertrophy
Grantee:Marcela Sorelli Carneiro Ramos
Support Opportunities: Regular Research Grants